Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

2020


• Eastham JA, Heller G, Halabi S, Monk P, Clinton SK, Szmulewitz RZ, Coleman J, Gleave M, Evans CP, Hillman DW, Beltran H, Taplin M-E, Hahn OM, Parsons JK, Small EJ, Mohler J, Morris MJ. CALGB 90203 (Alliance): Radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with clinically localized, high-


---

2018


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

Oncol 36[Suppl; abstr 557]. 2018.


2016


• Cheung WY, Mittmann N, Leighl NB, Cheung MC, Bradbury PA, Ng RCH, Chen BE, Ding K, Pater JL, Tu D, Hay AE. The economic impact of the transition from branded to generic oncology drugs. J Clin Oncol 34[Suppl; abstr 6520]. 2016.


• de Boer SM, Powell ME, Mleshkin LR, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles AW, Baron M-H, Kitchener HC, Nijman H, Kruitwagen RFP, Jurgenliemk-Shultz IM, Nout RA, Smit VTHBM, Putter H, Creutzberg CL. Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-


- Strasser-Weippl K, Sudan G, Ramjeessingh R, Shepherd LE, O'Shaughnessy J, Chen BE, Parulekar WR, Liedke PER, Goss PE. Outcomes of invasive ductal (ID) or invasive lobular (IL) early stage breast cancer in women treated with anastrozole or exemestane
Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)
• Arts KE, Kato D, Dancey J. Establishment of a baseline to measure academic clinical trial activity in Canada. J Clin Oncol 33[suppl; abstr e17547].


• Parimi S, Karachiwala H, Lin Y, Monzon JG, Tam VC, Chen EX, Dancey J, Tang PA. Critical assessment of phase 0 (Ph0) and window of opportunity (WOO) trials: Definitions and reporting. J Clin Oncol 33[suppl; abstr e17710].


• Pennigment MG. Full report of the TROG 03.01, NCIC CTG ES2 multinational phase III study in advanced esophageal cancer comparing palliation of dysphagia and quality of life in patients treated with radiotherapy or chemoradiotherapy. J Clin Oncol 33[(suppl 3; abstr 6)]. 2015.

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


metformin (Met) to placebo (Pl). J Clin Oncol 32:5s[suppl; abstr 542]. 2014.


2013

• Bar J, Ding K, Zhao H, Laurie SA, Han L, Shepherd FA, Addison CL, Goss GD, Dimitroulakos J, Bradbury PA. Exploratory analysis of angiotensin converting enzyme (ACE) and aldosterone (Ald) serum levels as prognostic and predictive biomarkers on the NCIC CTG BR24 trial. J Clin Oncol 31[suppl; abstr 8048], 2013.


- Moy B, Tu D, Richardson H, Maunsell E, Goss PE. NCIC CTG MAP.3: Symptoms and quality of life (QoL) among racial/ethnic minority women taking the aromatase inhibitor (AI) exemestane (XE) for breast cancer risk reduction. J Clin Oncol 31[suppl; abstr 6557], 2013.


- Renouf DJ, Parulekar W, Grigorieva J, Tu D, Moore MJ. Assessment of the association of the VeriStrat test with outcomes in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (G) with or without erlotinib (E) in the NCIC CTG PA.3 phase III trial. J Clin Oncol 31[suppl; abstr 4061], 2013.


2012


• Eisenhauer EA. Antiangiogenics in ovarian cancer: where are we now? Ann Oncol 23[suppl 9, abstr 54IN], ix40-ix41, 2012.


- Liedke PER, Chavarri-Guerra Y, Shepherd LE, Tu D, Pritchard KI, Goss PE. Vasomotor (VM) and musculoskeletal (MSK) symptoms and association with outcomes on extended adjuvant letrozole therapy: Analyses from NCIC CTG MA.17. J Clin Oncol 30[suppl, abstr 524], 2012.
- Pitz MW, MacNeil MV, Macdonald DR, Kakumanu AS, Thiessen B, Tsao MS, Kamel-


- Waldron JN, Parulekar W, O'Sullivan B, Chen BE, Montenegro A, Nabil A, Winquist E,


2011


• Cuffe S, Graziano S, Bourredjem A, Pignon J-P, Ezzalfani M, Seymour L, Strevel E, Burkes R, Capelletti M, Janne PA, Tsao MN, Shepherd FA. A pooled exploratory analysis of the impact of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy (ACT) in node negative (N0) non-small cell lung cancer (NSCLC). J Thoracic Oncol 6[6 suppl 2, abstr O42.01], S462, 2011.

suppl 2, abstr MO19.03], S641, 2011.


• Li X, Chen J, Wu Y, Tu D. Variable selections in the Cox proportional hazards model based on extended bayesian information criteria. 32nd Annual Conference of the International Society for Clinical Biostatistics, 2011.


• Meyer RM, Gospodarowicz M, Connors JM, Pearcey RG, Wells WA, Winter JN, Hornig SJ, Dar AR, Shustik C, Stewart DA, Crump M, Djurfeldt MS, Chen BE, Shepherd LE. Final Analysis of a Randomized Comparison of ABVD Chemotherapy with a Strategy


2010


- Alberts SR, Sargent DJ, Smyrk TC, Shields AF, Chan E, Goldberg RM, Gill S, Kahnberg MS, Thibodeau SN, Nair S. Adjuvant mFOLFOX6 with or without cetuximab in KRAS wild-type patients with resected stage III colon cancer: Results from NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 28[18s, abstr CRA3507], 2010.


Eisenhauer E. In search of intermediate endpoints. EORTC-NCI-AACR Symposium [abstr 29], 2010.


Radich JP, Kopecky KJ, Kamel-Reid S, Stock W, Paitetta E, Wadleigh M, Larson RA, Emanuel PD, Tallman MS, Lipton J, Couban S, Deininger MW, Appelbaum FR, Druker BJ. A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly


2010.


2009


- Craddock KJ, Buys TPH, Zhu CQ, Strumpf D, Pintillie M, Ding K, Seymour L, Jurisica I, Shepherd FA, Lam WL, Tsao M-S. High resolution genomic analysis of NSCLC reveals regions of DNA copy number gain that may be predictive of benefit from adjuvant chemotherapy. J Thoracic Oncol 4[9 suppl 1, abstr PD12.2.6], S580. 2009.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

with lapatinib or trastuzumab as first-line therapy for women with HER2/neu positive metastatic breast cancer (NCIC CTG MA.31/EGF108919). ASCO Breast Cancer Symposium, 2009.


- Kouroukis CT, Hafid T, Wong J, Kovacs MJ, Barr R, Findlay B, Shepherd L, Djurfeldt M, Ding K, Zhou L, Shustik C, Meyer R. Comorbidity, age and performance status are important predictors of outcome in older multiple myeloma patients treated with melphalan and corticosteroids; subgroup analysis from the National Cancer Institute of...


- Palm D, Broxterman J, Shepherd L, Parulekar W. Tracking patients on an intergroup oncology study. It’s a snap! Clinical Trials 6, 536, 2009.

- Petersdorf S, Kopecky K, Stuart RK, Larson RA, Nevi T, Senke L, Slovak ML, Tallman MS, Willman CL, Erba H, Appelbaum FR. Preliminary Results of Southwest...

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2008

- Bradbury PA, Tu D, Seymour L, Ng R, Zhu L, Isogai PK, Mittmann N, Evans WK, Shepherd FA, Leighl NB, on behalf of the NCIC CTG Working Group on Economic Analysis. Impact of clinical and molecular predictors of benefit from erlotinib in advanced...


- Lerner SP, Stein JP, Stadler WM, Groshen S, Tuazon E, Skinner DG, Raghavan D, Esrig D, Steinberg G, Hall C, Cote R. Results of the p53 targeted therapy trial for
patients with organ confined node negative bladder cancer treated with radical cystectomy. Society of Urologic Oncology, 2008.


- Pollak MN, Chapman JW, Pritchard KI, Krook JE, Dhaliwal HS, Vandenberg TA, Norris BD, Whelan TJ, Wilson CF, Shepherd LE. NCIC-CTG MA14 trial: Tamoxifen (tam) vs. tam + octreotide (oct)for adjuvant treatment of stage I or II postmenopausal breast


- Schell AJ, Young I, Hansen C, Chi KN, Taylor S. BRAF mutation status and growth factor receptor expression do not predict baseline factors or outcome in hormone refractory prostate carcinoma. United States and Canadian Academy of Pathology, 2008.


- Vergote I, Tropé CG, Amant F, Kristensen GB, Sardi JE, Ehlen T, Johnson N, Verheijen


2007

- Au H-J, Brundage M, Ringash J, Bezjak A, Palmer M, Richardson H, Lee CW, Maunsell


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


trial in prostate cancer of radiotherapy timing and hormone therapy duration after radical prostatectomy (MRC PR10, NCIC PR13, ISRCTN40814031). NCRI United Kingdom, 2007.


Tu D. Identification of patients who will benefit from a treatment based on their genetic profiles: Some examples and statistical issues. Workshop on Statistical Analysis of High-Throughput Genetic Data, 2007.


Chen CI, Kouroukis T, White D, Voralia M, Stadtmauer E, Wright J, Powers J, Eisenhauer E. Bortezomib is active in Waldenström's Macroglobulinemia (WM) - Results


O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman DG, Bramwell VH, Andruslis I, Pritchard KI. Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). Breast Cancer Research and Treatment 100[Suppl 1],S18, 2006.

O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman DG, Bramwell VH, Andruslis IL, Pritchard KI. Prognostic and predictive value of topoisomerase II alpha in a


maintaining hemoglobin $= 120$ G/L with erythropoietin during chemoradiation for cervical cancer. Int J Gynecol Cancer 16[3], 603-604, 2006.


2005


Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)


Goss PE, Ingle J, Tu D, Shepherd L, Pater J. NCIC CTG MA17: Disease free survival
according to estrogen receptor and progesterone receptor status of the primary tumor.


• Li D. Determinants of sample size and power in equivalence trials that compare binomial outcomes. Clinical Trials 2[Suppl 1], S59, 2005.

• Li D. Can more frequent regular group sequential tests help to make an earlier conclusion in clinical trials? A retrospective evaluation. Clinical Trials 2[Suppl 1], 2005.


• Maunsell E, Au H, Palmer M, Tu D, Whelan TJ, Goss PE, Davis A. Health-related quality of life in breast cancer survivors after 5 years of adjuvant tamoxifen. Quality of Life Research 14[9], 2092, 2005.

• Messerschmidt T, Koski B. Integrating SOPs into a comprehensive website document management system. Clinical Trials 2[Suppl 1], S50, 2005.


2005.

- Tu D. Nonparametric estimate and confidence intervals for the hazard ratio based on censored data. Clinical Trials 2[Suppl 1], S36, 2005.

2004

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Ding K. Point estimate following group sequential tests. ENAR Int Biometric Soc, 2004.


Ehrenberger H, Bacon M, Burkes K, Lillington L, Ward K, Zimmerman J. The
development of a virtual work group of the ONS Clinical Trials Nurses Special Interest Group: Keys to productivity. Oncology Nursing Society, 2003.


2002

- Bezjak A, Perrone F, Gallo C, Hirsh V, Seymour L, Plantedosi F, Shepherd F, Robbiati


Madarnas Y, Fine S, Sawka C, Shepherd L, Tannock I, Tu D, Levine M. Body size,


• Crump M, Tu D, Shepherd L, Levine E, Bramwell V, Pritchard K. Risk of acute leukemia


2000


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

21(2S), 114s, 2000.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


1999

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


• Tu D, Chen J, Shi P. A Bartlett type correction for Rao's score test in Cox proportional hazards model. Proc Joint Statistical Meetings, 1999.


1998

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

- Pater J, Beziak A, Osoba D, Zee B, Palmer M. Quality of life as an endpoint in NCIC


1997

- Dent S, Klaassen D, Pater J, Zee B, Whitehead M. Update of second primary malignancies and treatment results in women with early stage ovarian cancer.


1996

• Hall R. for MRC Advanced Bladder Cancer Working Party, EORTC GU Group, NCI Canada, Norwegian Bladder Cancer Group, Australian Bladder Cancer Study Group, Club Urologica Espanol de Tratamiento and FinBladder. Neo-adjuvant CMV chemotherapy and cystectomy or radiotherapy in muscle invasive bladder cancer. First
Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)

daunorubicin and cytosine arabinoside as induction therapy and all-trans retinoic acid versus observation as maintenance therapy for patients with previously untreated acute promyelocytic leukemia. Blood (ASH Annual Meeting Abstracts) 86[10 Suppl 1], 1996.

- Zee B. Phase II design for cancer clinical trials using multivariate endpoints. Biometric Society ENAR, 1996.

1995

- Latreille J, Johnston D, Laberge F, Stewart D, Rusthoven J, Nishimura L, Pater J, Zee B.
Use of granisetron and dexamethasone on day 2-7 following high dose cisplatin. Supportive Care in Cancer 3(5), 339, 1995.


- Lofters C, Zee B. Adding 5 HT3 antagonists to dexamethasone after 24 hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Eur.J.Can. 31A(suppl.5), 255, 1995.


- Lofters W, Zee B. Adding 5HT3 antagonists to dexamethasone after twenty four hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Supportive Care in Cancer 3(5), 339, 1995.


- Pater J, Zee B, Lofters W, Osoba D, Warr D, Palmer M, Chin C, Dempsey E. Effective...
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


1994


- Eisenhauer E, Bacon M, Atri M, Lemort M, Nolan R, Petroons P, Sauerbrei E, Florczyk


- Zee B, James K, Johnston D. Design and analysis of late randomization trials:


Tumour Research and Therapy, 1993.

- Paul N. The success of clinical trials depends on good communication. Joint meeting of EORTC SGDM and BODMA, 1993.

- Pater J, Niezgoda H, Zee B. Validation of the EORTC-QLC -- a comparison with four other instruments in a heterogenous group of cancer patients. Ann.Oncol. 3(Suppl.5), 175, 1992.
- Zee B. One-sided test for clinical trials with group sequential design that allow early
1991


1990

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

304, 1990.


1989

• Palmer M, Pater J. Comparison of errors in body surface area and initial doses in five clinical trials (C0.2, C0.3, HD.4, MA.4, OV.8). Controlled Clin.Trials 10(3), 351, 1989.

1988


1986

- Wallenstein S, Patel HI, Willan A. Use of baseline values in the two period two treatment crossover design. Biometric Society ENAR, 1986.


1984


1983


1981
